B. Cancer Research
1. Metastasis Suppressing Agent
Recent studies have shown that the expression of connexin 26, a protein component of gap junction, is increased in cancer cell lines, and suggested that the protein is involved in the mechanism of metastasis in cancer cells.
It has been revealed that MI-22 (metastasis inhibitor-22), which is a derivative of oleamide, does not only inhibit the connexin 26-mediated formation of gap junction between cancer and other cells but inhibits the spontaneous metastasis in vivo.
It has been revealed that MI-22 (metastasis inhibitor-22), which is a derivative of oleamide, does not only inhibit the connexin 26-mediated formation of gap junction between cancer and other cells but inhibits the spontaneous metastasis in vivo.
[Features]
1. Specific inhibition of connexin 26
2. Inhibition of gap junction intercellular communication
3. Inhibition of spontaneous metastasis in vivo
[References]
1. Ito, A., et al.,: J. Clin. Invest., 105, 1189 (2000).
2. Ito, A., et al.: Carcinogenesis, 25, 2015 (2004).
3. Ohba, Y., et al.: Int. J. Cancer, 121, 2801 (2007).
| Description | Wako Cat. No. (Pkg. Size) | Note |
|---|---|---|
| MI-22
[Metastasis Inhibitor-22][N1,N1,N7,N7-Tetraethyl-2,6-di[(Z)-7-hexadecenyl]-heptanediamide] C47H90N2O2 = 715.23 |
132-15043 (5 mg) | Keep and Ship at 2~10 ˚C in a dark place. Filled with inert gas. Please arrange for immediate use after opening. |
| 136-15041 (200 mg) |
2. Alkylating Compounds
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| 1,4-Butanediol Dimethanesulfonate [Busulfan] 97.0+% (cGC), CAS No. 55-98-1, C6H14O6S2 = 246.30 |
029-09352 (25 g) | Chronic myeloid leukemia | Keep and ship below 25 ˚C in a dark place |
|
Cyclophosphamide Monohydrate
97.0+% (Titration), CAS No. 6055-19-2,C7H15Cl2N2O2P•H2O = 279.10 |
030-12953 (1 g) | Breast cancer, Ovary cancer, Malignant lymphoma | Keep and ship at 2~10 ˚C in a dark place |
| 034-12951 (5 g) | |||
|
Dacarbazine 98.0+% (Potentiometric titration) CAS No. 4342-03-4, C6H10N6O = 182.18 |
047-29951 (200 mg) | Malignant melanoma, Malignant lymphoma | Keep and ship at 2~10 ˚C in a dark place |
| 043-29953 (1 g) | |||
| Ifosfamide 98.0+% (HPLC) CAS No. 3778-73-2, C7H15Cl2N2O2P = 261.09 |
090-05401 (50 mg) | Lung cancer, Prostate cancer | Keep and ship below 25 ˚C in a dark place |
| 096-05403 (500 mg) | |||
| Melphalan CAS No. 148-82-3, C13H18Cl2N2O2 = 305.20 |
135-15251 (100 mg) | Multiple myeloma | Keep and ship below 25 ˚C in a dark place |
| 131-15253 (1 g) | |||
| Procarbazine Hydrochloride 98.0+% (potentiometric titration) CAS No. 366-70-1, C12H19N3O • HCl = 257.76 |
161-22581 (100 mg) | Malignant lymphoma | Keep and ship below 25 ˚C in a dark place |
| 167-22583 (1 g) |
3. Antimetabolic Drugs
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Carmofur CAS No. 61422-45-5, C11H16FN3O3 = 257.26 |
035-20051 (1 g) | Digestive organs cancer, Breast cancer | Keep and ship at 2~10 ˚C in a dark place |
| 031-20053 (5 g) | |||
| Cytosine-1-β-D(+)-arabinofuranoside [Cytarabine] 98.0+% (HPLC), CAS No. 147-94-4, C9H13N3O5 = 243.22 |
030-11951 (100 mg) | Digestive organs cancer, Breast cancer, Acute myelogenous leukemia | Keep and ship at 2~10 ˚C in a dark place |
| 034-11954 (500 mg) | |||
| 036-11953 (1 g) | |||
| Doxifluridine CAS No. 3094-09-5, C9H11FN2O5 = 246.19 |
042-29901 (100 mg) | Digestive organs cancer, Breast cancer | Keep and ship below 25 ˚C in a dark place |
| 048-29903 (1 g) | |||
| 5-Fluorouracil [5-FU] 98.5+% (HPLC) CAS No. 51-21-8, C4H3FN2O2 = 130.08 |
068-01401 (1 g) | Breast cancer, Womb cancer, Digestive organs cancer | Keep and ship at RT in a dark place |
| 064-01403 (5 g) | |||
| 066-01402 (25 g) | |||
| Hydroxyurea [Hydroxycarbamide] 90.0+% (Titration) CAS No. 127-07-1, H2NCONHOH = 76.06 |
085-06653 (5 g) | Chronic myeloid leukemia | Keep and ship at 2~10 ˚C in a dark place |
| 089-06651 (10 g) | |||
| 6-Mercaptopurine Monohydrate 98.0~102.0% CAS No. 6112-76-1, C5H4N4S • H2O = 170.19 |
130-07991 (1 g) | Acute myelogenous leukemia, Chronic myeloid leukemia | Keep and ship at RT in a dark place |
| 136-07993 (5 g) | |||
| Methotrexate 98.0+% (HPLC) CAS No. 59-05-2, C20H22N8O5 = 454.44 |
139-13571 (100 mg) | Breast cancer, Chronic lymphoid leukemia | Keep and ship at RT in a dark place |
| 135-13573 (1 g) | |||
| 1-(2-Tetrahydrofuryl)-5-fluorouracil [Tegafur] 98.0+% (Titration), CAS No. 17902-23-7, C8H9FN2O3 = 200.17 |
206-10351 (1 g) | Digestive organs cancer, Breast cancer | Keep and ship below 25 ˚C in a dark place |
| 202-10353 ( 5 g) |
4. Antibiotics
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Aclarubicin Hydrochloride Potency: 860+μg/mg CAS No. 75443-99-1, C42H53NO15 • HCl = 843.34 |
017-12341 (10 mg) | Digestive organs cancer, Breast cancer | Keep at 2~10 ˚C in a dark place and ship at RT |
| Actinomycin D 97.0+% (HPLC) CAS No. 50-76-0, C62H86N12O16 = 1255.42 |
013-13421 (5 mg) | Wilms' tumor,Trophoblastic disease | Keep and ship at -20 ˚C in a dark place |
| Bleomycin Hydrochloride Potency: 1,400~2,000μg/mg CAS No. 67763-87-5, Molecular formula: Unspecified. |
028-07801 (10 mg) | Skin cancer,Head and neck cancer | Keep at 2~10 ˚C in a dark place and ship at RT |
| Daunorubicin Hydrochloride CAS No. 23541-50-6, C27H29NO10 • HCl = 563.98 |
043-30041 (5 mg) | Acute leukemia | Keep and ship at 2~10 ˚C in a dark place |
| 049-30043 (50 mg) | |||
| Doxorubicin Hydrochloride [Adriamycin HCl] Potency: 900+μg/mg CAS No. 25316-40-9, C27H29NO11 • HCl = 579.98 |
040-21521 (10 mg) | Digestive organs cancer, Malignant lymphoma | Keep at 2~10 ˚C in a dark place and ship at RT |
| 046-21523 (50 mg) | |||
| Epirubicin Hydrochloride CAS No. 56390-09-1, C27H29NO11 • HCl = 579.98 |
058-07561 (1 mg) | Malignant lymphoma, Digestive organs cancer | Keep and ship at 2~10 ˚C in a dark place |
| 054-07563 (5 mg) | |||
| Fumagillin 95+% (TLC), CAS No. 23110-15-8, C26H34O7 = 458.54 |
065-04071 (1 mg) | Antiangiogenic | Keep and ship at -20 ˚C in a dark place |
| 061-04073 (5 mg) | |||
| Mitomycin C Potency: 850+μg/mg CAS No. 50-07-7, C15H18N4O5 = 334.33 |
134-07911 (10 mg) | Digestive organs cancer, Womb cancer | Keep at 2~10 ˚C in a dark place and ship at RT |
| Mitomycin C with NaCl <Mitomycin: 2 mg; NaCl: 48 mg> CAS No. 50-07-7, C15H18N4O5 = 334.33 |
132-13201 (2 mg) | ||
| 138-13203 (2 mg x 10) | |||
| Peplomycin Sulfate Potency: 843+μg/mg CAS No. 70384-29-1, C61H88N18O21S2 • H2SO4 = 1,571.68 |
169-12011 (10 mg) | Skin cancer,Head and neck cancer | Keep at 2~10 ˚C in a dark place and ship at RT |
| Pirarubicin Potency: 950+μg/mg CAS No. 72496-41-4, C32H37NO12 = 627.64 |
160-14741 (25 mg) | Breast cancer,Head and neck cancer | Keep at 2~10 ˚C in a dark place and ship at RT |
5. Plant Alkaloids
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Paclitaxel 97.0+% (HPLC) CAS No. 33069-62-4, C47H51NO14 = 853.91 |
169-18616 (1 mg) | Ovary cancer, Stomach cancer, Breast cancer, Digestive organs cancer |
Keep and ship at 2~10 ˚C in a dark place. |
| 169-18611 (5 mg) | |||
| 165-18613 (25 mg) | |||
| 163-18614 (100 mg) | |||
| Vinblastine Sulfate 97.0+% (HPLC) CAS No. 143-67-9, C46H58N4O9 • H2SO4 = 909.05 |
221-00751 (10 mg) | Malignant lymphoma, Trophoblastic disease | Keep and ship at 2~10 ˚C in a dark place. |
| 227-00753 (50 mg) | |||
| Vindesine Sulfate 96.0+% (HPLC) CAS No. 59917-39-4, C43H55N5O7 • H2SO4 = 852.00 |
225-01631 (2 mg) | Lung cancer, Gullet cancer | Keep and ship at -80 ˚C in a dark place. |
| 221-01633 (10 mg) | |||
| Vinorelbine Ditartrate CAS No. 125317-39-7, C45H54N4O8 • 2C4H6O6 = 1,079.11 |
222-01641 (10 mg) | Lung cancer, Breast cancer | Keep and ship at -20 ˚C in a dark place.Filled with inert gas |
| 228-01643 (50 mg) |
6. Synthetic Hormone Agents
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Cholormadinone Acetate 98.0+% (HPLC) CAS No. 302-22-7, C23H29ClO4 = 404.93 |
035-15161 (1 g) | Prostate dilation syndrome | Keep and ship at RT in a dark place |
| 031-15163 (5 g) | |||
| Dexamethasone 98.0~102.0% (Titration) CAS No. 50-02-2, C22H29FO5 = 392.46 |
047-18863 (100 mg) | Malignant lymphoma, Breast cancer | Keep and ship at 2~10 ˚C in a dark place |
| 041-18861 (1 g) | |||
| Flutamide 98.0+% (HPLC) CAS No. 13311-84-7, C11H11F3N2O3 = 276.21 |
069-04851 (2 g) | Prostate cancer | Keep and ship below 25 ˚C in a dark place |
| 065-04853 (10 g) | |||
| Medroxyprogesterone Acetate 98.0+% (HPLC) CAS No. 71-58-9, C24H34O4 = 386.52 |
138-09991 (1 g) | Breast cancer,Womb cancer | Keep and ship at RT in a dark place |
| 134-09993 (5 g) | |||
| Prednisolone 97.0~103.0% (Absorptiometry) CAS No. 50-24-8, C21H28O5 = 360.45 |
165-11491 (1 g) | Malignant lymphoma, Breast cancer | Keep and ship at RT in a dark place |
| 161-11493 (5 g) | |||
| Tamoxifen Citrate 98.0+% (Titration) CAS No. 54965-24-1, C26H29NO • C6H8O7 = 563.64 |
209-14361 (250 mg) | Breast cancer | Keep and ship at 2~10 ˚C in a dark place. |
| 205-14363 (1 g) | |||
| 203-14364 (5 g) | |||
| 207-14362 (25 g) |
7. Platinum Complex
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Carboplatin 97.0+% (HPLC) CAS No. 41575-94-4, C6H12N2O4Pt = 371.25 |
039-16041 (25 mg) | Head and neck cancer, Lung cancer | Keep and ship at RT in a dark place |
| 035-16043 (250 mg) | |||
| Cisplatin 98.0+% (HPLC) CAS No. 15663-27-1, PtCl2(NH3)2 = 300.05 |
033-20091 (200 mg) | Bladder cancer,Head and neck cancer | Keep and ship at 2~10 ˚C in a dark place. Filled with inert gas |
| 039-20093 (2 g) | |||
| Oxaliplatin 97.0+% (HPLC) CAS No. 61825-94-3, C8H14N2O4Pt = 397.29 |
156-02691 (5 mg) | Colon cancer | Keep and ship at -20 ˚C in a dark place |
| 152-02693 (50 mg) |
8. Immunostimulant
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| Bestatin 96.0+% (HPLC) C16H24N2O4 = 308.37 |
027-14101 (100 mg) | nonspecific immunostimulant | Keep and ship at -20 ˚C in a dark place |
9. Others
| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---|---|---|
| all-trans-Retinoic Acid [Tretinoin] 97.0+% (HPLC) CAS No. 302-79-4, C20H28O2 = 300.44 |
186-01114 (50 mg) | Acute myelogenous leukemia | Keep and ship at -20 ˚C in a dark place |
| 182-01116 (100 mg) | |||
| 182-01111 (250 mg) | |||
| 188-01113 (1 g) |
Wako Product Update No.19 [ page. 4-6 ]